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ABSTRACT
Recent studies have demonstrated the utility of
recombinant adeno-associated viral (rAAV) vectors
in the generation of human knockout cell lines. The
efficiencywithwhichsuchcelllinescanbegenerated
using rAAV, in comparison with more extensively
described plasmid-based approaches, has not been
directly tested. In this report, we demonstrate that
targeting constructs delivered by rAAV vectors
were nearly 25-fold more efficient than transfected
plasmids that target the same exon. In addition, we
describe a novel vector configuration which we
term the synthetic exon promoter trap (SEPT). This
targeting element further improved the efficiency of
knockout generation and uniquely facilitated the
generation of knockin alterations. An rAAV-based
SEPT targeting construct was used to transfer a
mutant CTNNB1 allele, encoding an oncogenic form
of b-catenin, from one cell line to another. This versa-
tile method was thus shown to facilitate the efficient
integration of small, defined sequence alterations
into the chromosomes of cultured human cells.
INTRODUCTION
Gene targeting via homologous recombination is the most
deﬁnitive means of assessing gene function. While routinely
applied to diverse organisms such as bacteria, yeast and
rodents, established methods of gene targeting have been sig-
niﬁcantly less efﬁcient when applied to human cell lines (1).
The comparatively low rate at which homologous recombi-
nants can be recovered from human cell populations seems to
be due to a lower rate at which exogenous DNA can be intro-
duced into cells and integrated into the genome, and possibly
to a lower rate of homologous recombination as well. There
have been three successful approaches to circumventing these
obstacles. One approach has been to optimize the delivery of
intact targeting DNAs so that they are introduced into a large
proportion of the target cell population while avoiding intra-
cellular degradation (2). A second approach has been to
conﬁgure targeting vectors so that they preferentially allow
growth, under selection, of clones that result from homologous
integration rather than random, non-homologous integration
(3). A third approach, has been to increase the rate of homo-
logous recombination at the locus of interest. Recently, it has
been shown that this can be accomplished by the generation
of site-speciﬁc DNA breaks (4).
The most common means of DNA delivery is by electro-
poration or lipofection of linearized plasmid DNA. Electro-
poration of targeting DNAs has been shown to result in an
improved rate of homologous recombination, possibly due to a
reduction in the extent to which exogenous DNA is degraded
under these conditions (2). Because such methods are rela-
tively inefﬁcient in many human cell types, lipofection has
been the method of choice for the generation of transgenic and
knockout human cell lines. The efﬁcient generation of human
cell knockouts was recently achieved by the use of recombi-
nant adeno-associated viruses (rAAV) (5). The enormous
potential of this method was underscored by the demonstration
that targeted human cells could be detected without selection
for integration, suggesting that both integration and homo-
logous recombination were greatly favored.
A major advance in the targeting of human genes was the
development of the promoter-trap targeting construct (6).
Most targeting methods use the expression of a marker gene
as a means of selecting clones in which the targeting construct
has stably integrated into the genome. The type of construct
used most commonly to target mouse genes includes a con-
stitutively active promoter that drives expression of the
selectable marker gene (3). Such a construct does not have
to integrate near an endogenous promoter in order to give
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doi:10.1093/nar/gni160rise to a drug resistant transgenic clone. The promoter trap
strategy, in contrast, requires integration of a promoterless
construct in the proximity of an active endogenous promoter,
which then drives the expression of the marker gene (6).
Accordingly, promoter trap vectors result in the generation
of a smaller number of drug resistant clones, but in many
cases a high proportion of these clones are found to result
from homologous integration. First described by Hanson
and Sedivy (6), promoter-trap targeting vectors have been
successfully employed in the targeting of many human loci.
Such techniques are generally considered the method of
choice for plasmid-based gene targeting.
This high targeting efﬁciency of promoter-trap constructs
comes at the price of limited versatility. The use of a promoter
trap requires the disruption of an exon and the insertion of
a selectable marker, expressed either as an in-frame fusion
with the endogenous gene or in a separate cistron by means
of an internal ribosomal entry site (IRES). Unless the targeted
exon is painstakingly reproduced elsewhere in the targeting
construct, the disruption of an exogenous exon will result in
a loss of gene function. Subtle alterations that preserve endo-
genous exons are not generally feasible by current methods.
Attempts to use rAAV to introduce human gene mutations
have yielded promising results. Using rAAV to target the
human HPRT gene, Russell and coworkers (7) succeeded
in introducing single base mutations that conferred resistance
to the selective agent 6-thioguanine. While these results
are encouraging, most desired genetic alterations would not
cause a selectable growth advantage. The targeting of a
nonselectable gene, and subsequent recovery of a knockin
cell line, would clearly require a method that facilitates
high-efﬁciency gene targeting.
One of the major goals of this study was to improve the
versatility of the promoter-trap approach and to devise a
general method for altering human genes. In this report, we
describe a targeting strategy, the synthetic exon promoter trap
(SEPT), that can be used in conjunction with rAAV-based
gene targeting. We demonstrate the broad utility of this
approach by transferring a functional, pathogenic mutation
in the CTNNB1 gene from one colorectal cancer cell line to
another.Thisversatilestrategyshouldbereadilyapplicablefor
generating knockout or knockin cell lines for any transcrip-
tionally active human gene.
MATERIALS AND METHODS
Cells and cell culture reagents
The human colorectal cancer cell lines HCT116 and DLD1
were grown in McCoy’s 5A modiﬁed medium (Invitrogen)
supplemented with 10% fetal bovine serum (HyClone) and
penicillin/streptomycin (Invitrogen).
Targeting constructs
Regions of homology at the P53 and CTNNB1 loci were
ampliﬁed from genomic DNA obtained from HCT116 cells,
using Platinum Taq DNA Polymerase High Fidelity (Invitro-
gen), as per the manufacturer’s recommendations. Unique
restriction sites were embedded within the oligonucleotide
primers used to amplify all plasmid components. rAAV
targeting constructs were assembled by ligation of homology
arms and selectable marker cassettes, which were inserted
between the two NotI sites of pAAV-MCS, an AAV shuttle
vector that carries the two inverted terminal repeat (ITR)
sequences necessary for viral packaging (Stratagene). The
targeting plasmid pBCATN was constructed by ligating
the homology arms, LoxP sites and neomycin transferase
(neo) cassette between the HindIII and SalI sites of pBR322.
pAAV-BCATN is a derivative of pBCATN in which neo and 1
kb of each homology arm were ampliﬁed by high ﬁdelity PCR
and inserted into pAAV-MCS.
Construction of the SEPT targeting cassette
The SEPT cassette begins with a hybrid 50-regulatory element
developed by Huang and Gorman (8), which contains a short
length of intron sequence followed by a splice acceptor
derived from an IgG variable region. The synthetic exon con-
tains an IRES, which permits the translation of the neo open
reading frame (ORF) from RNA transcripts initiating from
upstream exons (9), followed by a polyadenylation site. The
plasmid pSEPT contains the SEPT cassette ﬂanked by tandem
LoxP sites oriented so that transient expression of the Cre
recombinase results in excision of all sequences between
them. Details of plasmid assembly are available upon request.
Packaging of rAAV targeting constructs
Infectious rAAV stocks were produced with the AAV Helper-
Free System (Stratagene) according to the manufacturer’s
protocols. Brieﬂy, ITR-containing targeting constructs were
co-transfected with the plasmids pAAV-RC and pHELPER.
Approximately 5 · 10
6 AAV-293 cells in a 75 cm2 ﬂask were
transfected with a mixture of 2.5 mg of each of the above three
plasmids, using 54 ml of Lipofectamine (Invitrogen) as per
manufacturer’s protocol. The transfection was performed in
serum-free conditions using OptiMEM medium (Invitrogen).
Two days after transfection, cells were scraped into 1 ml of
phosphate-buffered saline and frozen and thawed three times.
The crude lysate was clariﬁed by centrifugation and the super-
natant was divided into aliquots and stored at  80 C. The titer
of these rAAV stocks was  10
6 viral particles/ml.
Gene targeting and isolation of recombinant cell lines
Cells were grown in 25 cm
2 ﬂasks and infected with rAAV
when  75% conﬂuent. At the time of infection, medium
was aspirated and 4 ml of medium containing 50–250 mlo f
rAAV lysate (0.5–2.5 · 10
5 viral particles) was added to each
ﬂask. Cells were washed with Hanks buffered saline solution
and detached with trypsin (Invitrogen), 24 h after infection.
Cells were replated in eight 96-well plates in medium
containing geneticin (Invitrogen) at a ﬁnal concentration of
0.4 mg/ml. Drug resistant colonies were grown for 3–4 weeks.
At the end of the selection period, genomic DNA was
extracted from single clones growing in 96-well plates
using the Wizard SV 96 Genomic DNA Puriﬁcation System
(Promega) and eluted in 100 ml of the supplied elution buffer.
Locus-speciﬁcintegrationwasassessed byPCRusingaprimer
that annealed outside the homology region and another that
annealed within neo. Positive clones were conﬁrmed by PCR
across both homology arms.
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elements and Southern blot analysis
To remove the SEPT cassette from correctly targeted clones,
cells were infected with an adenovirus that expresses the Cre
recombinase, as described (10). Cells were plated at limiting
dilution in nonselective medium, 24 h after infection. After
2 weeks, single cell clones were plated in duplicate and
0.4 mg/ml geneticin was added to one set of wells. After
1 week of growth, clones that were geneticin-sensitive were
expanded for further analysis. Southern blot analysis was
performed as in (10). Genomic DNA was digested with
XbaI. Blots were probed with a 565 bp probe derived from
CTNNB1 intron 6.
RT–PCR and DNA sequencing
Total RNA was isolated using the Qiagen RNeasy kit
(Qiagen). RT–PCR was performed with the SuperScript
One-Step with Platinum Taq System (Invitrogen), using
0.5 mg of RNA as template. Primer-speciﬁc cDNA was ampli-
ﬁed for 40 cycles at an annealing temperature of 58 C, as per
manufacturer’s recommendations. The primers speciﬁc for the
b-catenin gene transcript were 50-AAATCCAGCG-
TGGACAATGG-30, which anneals within exon 2, and 50-
CTAGAGCAGACAGATAGCACC-30, which anneals within
exon 7.
RESULTS AND DISCUSSION
Delivery of targeting constructs: rAAV
versus plasmid DNA
Gene targeting in human cells has been accomplished with
various types of targeting constructs and vectors (1). Most
reports of human cell knockouts employ only one targeting
strategy, which makes it difﬁcult to compare the efﬁciencies
of different methods. It is clear that targeting efﬁciencies
vary broadly between loci, a fact that further complicates a
comparison of different approaches (1).
In a recent study of rAAV-mediated gene targeting,
Kohli et al. (11) reported achieving efﬁciencies that ranged
between0.4 and 13% using promoter-containing constructs. In
comparison, efﬁciencies of gene targeting with plasmid con-
structs have been reported to range from 0.01 to 20% (12,13).
However, most of these studies employed promoter trap
constructs. Thus, while rAAV-mediated gene targeting is
clearly highly efﬁcient, there is in fact a signiﬁcant amount
of overlap between published rates at which homologous
recombinant clones have been recovered using the rAAV-
and plasmid-based methods. A recent study that assessed
the ability of exogenous DNA to quantitatively alter an inte-
grated reporter gene showed that rAAV was signiﬁcantly more
efﬁcient at gene targeting when compared with plasmid DNA
(4). Taken together, these disparate studies suggest that
rAAV-based methods should yield a higher proportion of
desired recombinant cell lines than plasmid-based methods,
yet the published rates at which targeted clones have been
recovered do not demonstrate a clear difference. We specu-
lated that the overlap in the published targeting efﬁciencies
might therefore be due to the differential utilization of
promoter-traps in different laboratories. Differences between
the recombination rates at different loci may further cloud this
issue. The factors that contribute to targeting efﬁciency at a
given locus are unknown, but it has been speculated that the
presence of repeat elements within regions of homology may
reduce efﬁciency (11).
To directly compare rAAV and plasmid transfection
methods at the same locus, we measured the rate of recovery
of homologous recombinant clones resulting from the inser-
tion of a neo cassette into exon 3 of the CTNNB1 gene, which
encodes b-catenin. Both the targeting plasmid and the rAAV
had an identical conﬁguration at the point of insertion, and
were designed to disrupt exon 3 and thereby knockout gene
function. In this scheme, the neo gene, ﬂanked by regions of
homology to CTNNB1, was expressed as an in-frame fusion
with the ﬁrst 32 amino acids encoded by b-catenin and driven
by the endogenous promoter that was outside the region of
homology.
To maximize the potential efﬁciency of the CTNNB1 tar-
geting plasmid, we incorporated a lengthy region of chromo-
somal homology, spanning a total of 8.5 kb, into the plasmid
construct pBCATN (Figure 1). The packaging capacity of
rAAV is  4.7 kb, which limited the maximum amount of
chromosomal homology that could be incorporated into the
viral construct, pAAV-BCATN. Homology arms were accord-
ingly shorter and a total of 2229 bp of homology was used.
We chose to focus our initial efforts on gene targeting in the
cell line HCT116. This cell line is a widely used diploid
colorectalcancercelllineand hasbeen employedinthe major-
ity of human gene targeting studies to date. Both rAAV- and
plasmid-based approaches have been used successfully in
this line. Which method is more efﬁcient? To address this
important question, HCT116 cells were either infected with
rAAV derived from pAAV-BCATN or transfected with
the targeting plasmid pBCATN. Two days later, cells were
detached and reseeded into multiwell plates containing selec-
tive medium and then grown under selection for an additional
Figure 1. Comparisonof gene targeting at CTNNB1 using a targeting plasmid,
pBCATN (upper construct)and an rAAV derivedfrom pAAV-BCATN (lower
construct).Bothconstructs havethe identicalconfiguration aroundthe pointof
insertion into exon 3. The lengths of the homology arms are as indicated. PCR
with the primer pairs P1 and P2 (for rAAV) and P1 and P3 (for plasmid
pBCATN) were used to screen for homologous integration. Exons are blue
boxes; LoxP sites are indicated by red triangles. ITR, inverted terminal repeat;
neo, neomycin transferase ORF; pA, polyadenylation signal sequence.
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rAAV than transfection of the plasmid (Table 1), indicating
a higher rate of stable neo integration. It is important to note
that while the plasmid transfection was performed under pre-
viously optimized conditions, the rAAV infection was per-
formed with an arbitrary amount of a low-titer viral stock.
It is therefore probable that much higher colony formation
rates may be achieved by adjusting the multiplicity of
infection (MOI). Importantly, increasing the MOI not only
increases the amount of viral gene delivery but has also
been reported to increase the frequency of targeting (14).
Screening the neo resistant clones by PCR to assess
homologous integration revealed correct targeting in 1% of
the clones generated by integration of the plasmid construct,
while23%oftherAAVderivedclonesweretargeted(Table1).
A previous study has reported a targeting efﬁciency at
CTNNB1 of 12% using a promoterless plasmid-based con-
struct (15). The previously described construct was signiﬁ-
cantly different from the one used here; it was designed to
delete a large region of CTNNB1 and therefore the homology
arms encompass a different region of the gene. Indeed, the
difﬁcultiesinherentincomparingdifferentconstructsprovided
the rationale for this experiment. Comparision of these studies
suggest that gene targeting efﬁciency varies not only between
genes, but can also vary at different positions within a gene.
Gene targeting using a synthetic exon promoter trap
As described above, an important development that has facili-
tated the targeted disruption of numerous human genes is a
feature of targeting constructs known as a promoter trap (3). A
signiﬁcantly higher proportion of homologous recombinants
can be obtained with this approach because the selectable
marker gene can only be expressed if the construct integrates
within an actively transcribed gene. The construct itself
contains no promoter and therefore random integration is
less probable to result in expression of the selectable marker.
While powerful, this approach requires either the disruption of
an endogenous exon or a more complex strategy wherein an
endogenous exon is duplicated and then removed (16).
We designed a targeting element that we call the SEPT. As
its name implies, the SEPT strategy is to integrate a synthetic
exon into the chromosomal locus of interest by homologous
recombination. This exogenously introduced exon contains a
splice acceptor followed by an IRES, a neo ORF and a poly-
adenylation signal sequence (Figure 2A and B). The exon
cassette is preceded by a short synthetic intron and ﬂanked
by LoxP sites, so that all introduced sequences can be easily
removed from the genomic locus by expression of the Cre
recombinase. SEPT is a promoterless conﬁguration and
therefore expression of the neo marker requires integration
into the proximity of an active promoter. A similar vector
conﬁguration has been used in mouse cells to target and
trap developmentally-regulated genes (17).
WecomparedtheefﬁciencyoftheSEPT approachinhuman
cancer cells with similar constructs in which neo expression
was driven by the herpesvirus thymidine kinase (tk) gene
promoter. We examined targeting at two different loci:
P53, which encodes the tumor suppressor protein p53, and
CTNNB1, which encodes b-catenin. For each locus, the two
targeting constructs tested had identical homology arms.
To test the capabilities of the SEPT approach, the CTNNB1
targeting constructs were designed to knockin a previously
described oncogenic mutation (Figure 2A). The P53 targeting
constructs were designed to delete endogenous exon 2,
thereby resulting in a knockout allele (Figure 2B). Homolog-
ous recombination of these constructs at the endogenous locus
results in the integration of the selectable marker into intron 2
Table 1. Gene targeting with rAAV versus plasmid transfection
Cells treated Colony
formation rate
Colonies
screened
PCR positive
colonies
Targeting
efficiency
a
Plasmid
b 6 · 10
7 2.5 · 10
 5 576 5 0.009
rAAV
c 5 · 10
6 1 · 10
 3 60 14 0.23
aTargeting efficiency is defined as the proportion of colonies screened that
were homologous recombinants.
bTargeting plasmid pBCATN, as described in Materials and Methods.
cGenerated by packaging pAAV-BCATN plasmid, as described in Materials
and Methods.
Figure 2. Gene targeting with the SEPT targeting element. Constructs were
designed to knockin a pathogenic mutation into CTNNB1 exon 3 (A), or to
knockout exon 2 of P53 (B). At each locus, a construct containing a SEPT
element was directly compared with a construct containing a thymidine kinase
promoter that was otherwise identical. Each locus is shown after targeting and
subsequentremovalofthetargetingcassettebyexpressionofCrerecombinase.
Exonsareboxes;themodifiedCTNNB1exon3isshowninblack;LoxPsitesare
red triangles. Repeat elements within the regions of homology detected by
RepeatMasker are shown in green above each targeted locus. tk, thymidine
kinase promoter; SA, splice acceptor; IRES, internal ribosomal entry site.
Remaining abbreviations are as defined in Figure 1.
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ofCTNNB1,a3bpdeletioninexon3thatdeletesthe codonfor
serine 45 (18). The right homology arm of the two CTNNB1
constructs was derived from the mutated allele of HCT116 and
thus contained the oncogenic mutation.
As shown in Table 2, infection with the tk promoter-
containing constructs resulted in greater numbers of drug
resistant colonies than did the SEPT constructs. The high
rate of colony formation is consistent with previous observa-
tions that integration of a promoterless plasmid construct
is less probable to give rise to a drug resistant clone (3).
This is presumably because integration into a random location
is much less probable to result in expression of the selectable
marker. The efﬁciency of targeting, as measured by the pro-
portion of the drug resistant clones that resulted from homo-
logous recombination, was higher for the SEPT constructs
(Table 2). Compared with the tk promoter-containing con-
structs, the SEPT constructs were  5- and 7-fold more efﬁ-
cient at targeting the CTNNB1 and P53 loci, respectively.
There have been several previous studies in which P53 has
been targeted in HCT116 using plasmid-based methods
(19,20). These efforts used a promoter trap plasmid construct
containing extensive regions of homologyto knockout P53,b y
deletion of exon 2, with an efﬁciency of  0.001. In the present
study, the use of the SEPT-containing rAAV to target the same
exon resulted in a targeting efﬁciency that was more two
orders of magnitude higher, a signiﬁcant improvement.
For both the tk- and SEPT-containing rAAV used in our
study, the targeting frequencies obtained were  10-fold
higher at P53 than at the CTNNB1 locus (Table 2). Since
the same methods were used to target both loci in the same
cell line, the different targeting rates must therefore be
attributable to inherent differences in the extent to which
recombination occurred within the regions of homology.
One possibility is that repeat elements might adversely affect
recombination at the desired locus by favoring promiscuous
recombination with repeats in other locations. However, scan-
ning the P53 sequences used in the targeting constructs with
RepeatMasker (http://repeatmasker.genome.washington.edu/),
revealed that nearly 40% of this region was made up of
identiﬁable repeats, while <10% of the CTNNB1 homology
region was composed of repeat sequence (Figure 2). The tar-
geting frequencies at the two loci tested were thus inversely
proportional to the amount of repeats detected within the
regions of homology, the opposite of what might have been
expected. The different rates of homologous recombination
that we observed may have resulted from unrecognized
sequence elements or aspects of local chromosome structure
that are not understood. Further studies at additional loci are
required to determine whether there is a direct relationship
between repeats and targeting efﬁciency.
Notably, we observed an  10-fold difference between the
efﬁciency of the knockout construct that disrupted CTNNB1
exon 3 (23%) and the knockin SEPT construct that was inte-
grated within intron 2 (2%). Since the region of homology
used in these two constructs were very similar, though
not identical, it would seem probable that the difference
lay in the conﬁguration of the selectable marker. One explana-
tion would be that the SEPT cassette was more efﬁcient at
splicing to upstream exons than the disrupted exon 3
engineered into the knockout vector. This would be
predicted to result in a higher rate of expression of randomly
integrated targeting DNAs and a correspondingly lower rate of
targeting.
Derivation of a knockin human cell line
using rAAV and SEPT
While we were able to quantify targeting of CTNNB1 in
HCT116, the mutated allele that is already present in this
cell line made it less suitable for demonstrating a functional
knockin alteration. To show that we could alter CTNNB1 and
achieve expression of the altered allele, we used the SEPT-
containing rAAV in DLD1, a colorectal cancer cell line that
has two wild-type CTNNB1 alleles (18). We used exactly the
same methods to generate and screen transgenic clones that
had been used in HCT116. Screening 109 geneticin-resistant
clones resulted in the identiﬁcation of 20 positive clones,
a targeting efﬁciency of 18%. This was 10-fold higher than
the targeting efﬁciency of this construct in HCT116 as shown
in Table 2. This result suggests that the SEPT targeting
approach will be generally useful in a variety of human
cell lines.
To restore the general architecture of the CTNNB1 gene
and thereby facilitate expression of a full length b-catenin
transcript, we removed the SEPT cassette with the use of a
Cre-expressing recombinant adenovirus. Subclones in which
neo had been excised were identiﬁed functionally, by virtue
of their sensitivity to geneticin. Correct targeting and removal
of the SEPT cassette was conﬁrmed by Southern blot
(Figure 3A,B). The observed bands were consistent with
the homologous integration of the SEPT cassette and its sub-
sequent removal by Cre (Figure 3B).
Expression of the introduced, mutant form of b-catenin was
demonstrated by RT–PCR ampliﬁcation followed by DNA
sequencing. PCR primers annealed to sequences encoded by
exons 2 and 7, the latter was downstream of the homology
region. A total of 1072 bp of b-catenin encoding cDNA was
ampliﬁed. All PCR products were consistent with full-length
transcripts (data not shown). These were gel isolated and
sequenced. DLD1 cells expressed a homogenous population
of wild-type transcripts, as expected (Figure 3C). In contrast,
the knockin clones showed a homogeneous sequence between
the primer annealing site and the serine 45 codon, after
which the sequence became heterogeneous. Inspection of the
sequence electropherograms showed the presence of two spe-
cies with sequences offset by 3 bp. The height of the electro-
pherogram peaks indicated the presence of roughly the same
Table 2. Gene targeting with the SEPT element
Locus Cells
infected
Colony
formation
rate
Colonies
screened
PCR positive
colonies
Targeting
efficiency
a
CTNNB1
tk promoter 5 · 10
6 0.033 741 3 0.004
SEPT 5 · 10
6 0.004 170 3 0.018
P53
tk promoter 5 · 10
6 0.015 95 4 0.042
SEPT 5 · 10
6 0.006 94 26 0.28
aTargeting efficiency is defined as the proportion of colonies screened that
were homologous recombinants.
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the knockin allele was expressed at roughly the same level as
the untargeted, wild-type allele.
In summary, we have ampliﬁed an oncogenic mutation
from one cell line and, by incorporating this mutation into
a targeting construct, transferred this mutation into another
cell line that is wild-type for this gene. It would have been
equallystraightforwardtointroducethismutation,oranyother
short alteration, into a targeting construct by site-directed
mutagenesis.
A key attribute of the SEPT approach is its versatility. The
SEPT cassette isgenericand canbeusedwithoutmodiﬁcation.
To create a targeting construct, the SEPT cassette is simply
ligated between two regions of homology to the gene of
interest, which are generated by PCR. The simplicity of
this scheme contrasts with other promoter trap approaches,
in which the junction between the endogenous exon to be
targeted and the selectable marker gene must be laboriously
customized for each gene. Recently, a novel method has been
described that employs a fusion PCR technique to streamline
the construction of rAAV for gene targeting (11). Fusion PCR
could be similarly employed to generate SEPT-containing
constructs with only minor modiﬁcations to the published
protocol, further streamlining this method.
In this study, we show that the combined use of rAAV and
the SEPT approach can signiﬁcantly improve the efﬁciency of
gene targeting in human cells. This method does not require
the disruption of an endogenous exon and can therefore be
used for the generation of human gene knockin cell lines. We
anticipate that human cell knockins will be powerful new tools
for studying how gene mutants and variants contribute to
disease and affect responses to therapy.
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